{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:17:23Z","timestamp":1790777843544,"version":"4.1.0"},"reference-count":183,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.blre.2022.100969","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T04:58:11Z","timestamp":1651813091000},"page":"100969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Neoantigens \u2013 the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders"],"prefix":"10.1016","volume":"56","author":[{"given":"Muhammed B.","family":"Sabdia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Patch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hennes","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001111","article-title":"Antigen processing and presentation in cancer immunotherapy","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of Antigen Processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0020","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri2368","article-title":"The known unknowns of antigen processing and presentation","volume":"8","author":"Vyas","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","article-title":"Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire","volume":"17","author":"Haen","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","article-title":"Getting personal with neoantigen-based therapeutic cancer vaccines","volume":"1","author":"Hacohen","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"15","key":"10.1016\/j.blre.2022.100969_bb0040","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-20-4314","article-title":"Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms","volume":"27","author":"Abbott","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6184","key":"10.1016\/j.blre.2022.100969_bb0045","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science."},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.blre.2022.100969_bb0055","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"issue":"7457","key":"10.1016\/j.blre.2022.100969_bb0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature."},{"issue":"7647","key":"10.1016\/j.blre.2022.100969_bb0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2326-6066.CIR-13-0227","article-title":"HLA-binding properties of tumor neoepitopes in humans","volume":"2","author":"Fritsch","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"7463","key":"10.1016\/j.blre.2022.100969_bb0075","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"10.1016\/j.blre.2022.100969_bb0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2021.02.023","article-title":"Gene fusion neoantigens: Emerging targets for cancer immunotherapy","volume":"506","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0085","article-title":"Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer","volume":"22","author":"Oka","year":"2021","journal-title":"Genome Biol"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0090","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1172\/JCI137723","article-title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia","volume":"130","author":"Biernacki","year":"2020","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100969_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.isci.2019.10.028","article-title":"The landscape of tumor fusion neoantigens: a pan-cancer analysis","volume":"21","author":"Wei","year":"2019","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2018.07.008","article-title":"Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens","volume":"34","author":"Hoyos","year":"2018","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.blre.2022.100969_bb0115","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2022.100969_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-020-00220-5","article-title":"The biological function and clinical significance of SF3B1 mutations in cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomarker Res"},{"key":"10.1016\/j.blre.2022.100969_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15171-6","article-title":"Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns","volume":"11","author":"Tang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100969_bb0135","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","article-title":"Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes","volume":"11","author":"Chong","year":"2020","journal-title":"Nat Commun"},{"issue":"203","key":"10.1016\/j.blre.2022.100969_bb0140","doi-asserted-by":"crossref","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/2326-6066.CIR-16-0280","article-title":"Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia","volume":"5","author":"Malaker","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0150","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14789450.2020.1845147","article-title":"Using phosphoproteomics and next generation sequencing to discover novel therapeutic targets in patient antibodies","volume":"17","author":"Zeneyedpour","year":"2020","journal-title":"Expert Rev Proteomics"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0155","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/2326-6066.CIR-19-0894","article-title":"Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma","volume":"8","author":"Faridi","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"6310","key":"10.1016\/j.blre.2022.100969_bb0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1126\/science.aaf4384","article-title":"A large fraction of HLA class I ligands are proteasome-generated spliced peptides","volume":"354","author":"Liepe","year":"2016","journal-title":"Science."},{"issue":"51","key":"10.1016\/j.blre.2022.100969_bb0165","doi-asserted-by":"crossref","first-page":"21170","DOI":"10.1074\/jbc.R117.807560","article-title":"Peptide splicing by the proteasome","volume":"292","author":"Vigneron","year":"2017","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0170","first-page":"487","article-title":"Targeting public neoantigens for cancer immunotherapy. Nature","volume":"2","author":"Pearlman","year":"2021","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0175","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1172\/JCI126116","article-title":"Cellular therapy against public neoantigens","volume":"129","author":"Armistead","year":"2019","journal-title":"J Clin Investig"},{"issue":"6230","key":"10.1016\/j.blre.2022.100969_bb0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science."},{"issue":"7239","key":"10.1016\/j.blre.2022.100969_bb0190","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.blre.2022.100969_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00839","article-title":"Structural variants as a basis for targeted therapies in hematological malignancies","volume":"9","author":"Sch\u00fctte","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100969_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2018.00080","article-title":"The cancer spliceome: reprograming of alternative splicing in cancer","volume":"5","author":"El Marabti","year":"2018","journal-title":"Front Mol Biosci"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0205","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100969_bb0210","article-title":"Alternative splicing and cancer: a systematic review","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0215","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0220","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0225","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy","volume":"103","author":"Marie de","year":"2018","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nri3804","article-title":"Dynamics of B cells in germinal centres","volume":"15","author":"De Silva","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"7180","key":"10.1016\/j.blre.2022.100969_bb0235","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature06547","article-title":"Two levels of protection for the B cell genome during somatic hypermutation","volume":"451","author":"Liu","year":"2008","journal-title":"Nature."},{"issue":"5370","key":"10.1016\/j.blre.2022.100969_bb0240","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.280.5370.1750","article-title":"Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes","volume":"280","author":"Shen Hong","year":"1998","journal-title":"Science."},{"key":"10.1016\/j.blre.2022.100969_bb0245","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00438","article-title":"Mutating for good: DNA damage responses during somatic hypermutation","volume":"10","author":"Pilzecker","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.100969_bb0250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/978-1-61779-842-9_32","article-title":"IMGT(\u00ae) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT\/V-QUEST and IMGT\/HighV-QUEST for NGS","volume":"882","author":"Alamyar","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"W1","key":"10.1016\/j.blre.2022.100969_bb0255","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"Ye","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0260","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100969_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0730-x","article-title":"Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.blre.2022.100969_bb0270","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.leu.2403323","article-title":"Activation-induced cytidine deaminase expression in follicular lymphoma: association between AID expression and ongoing mutation in FL","volume":"18","author":"Hardianti","year":"2004","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0275","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0280","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/76243","article-title":"Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies","volume":"6","author":"Trojan","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0285","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.86.1.282","article-title":"B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells","volume":"86","author":"Weiss","year":"1989","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0290","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0008-8749(92)90259-R","article-title":"Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor: III. MHC class I-Restricted CTL recognizes the processed form(s) of idiotype","volume":"144","author":"Chakrabarti","year":"1992","journal-title":"Cell Immunol"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0295","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.4049\/jimmunol.1400075","article-title":"The MHC Class II Cofactor HLA-DM Interacts with Ig in B Cells","volume":"193","author":"Macmillan","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100969_bb0300","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0092-8674(91)90506-T","article-title":"MHC class II - Restricted presentation of intracellular antigen","volume":"64","author":"Weiss","year":"1991","journal-title":"Cell."},{"issue":"7662","key":"10.1016\/j.blre.2022.100969_bb0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature."},{"key":"10.1016\/j.blre.2022.100969_bb0310","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0315","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"issue":"10304","key":"10.1016\/j.blre.2022.100969_bb0320","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0325","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"498","key":"10.1016\/j.blre.2022.100969_bb0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0335","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2014-04-567933","article-title":"Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia","volume":"124","author":"Rajasagi","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100969_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01392","article-title":"Determinants for neoantigen identification","volume":"10","author":"Garcia-Garijo","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.100969_bb0345","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0606-6","article-title":"Complex structural variants in Mendelian disorders: identification and breakpoint resolution using short- and long-read genome sequencing","volume":"10","author":"Sanchis-Juan","year":"2018","journal-title":"Genome Med"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0350","doi-asserted-by":"crossref","DOI":"10.5808\/GI.2019.17.3.e23","article-title":"Identification of neoantigens derived from alternative splicing and RNA modification","volume":"17","author":"Park","year":"2019","journal-title":"Genomics Inform"},{"key":"10.1016\/j.blre.2022.100969_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.593989","article-title":"Systematically characterizing A-to-I RNA editing neoantigens in cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0360","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/s41598-019-43282-8","article-title":"Deleterious effects of formalin-fixation and delays to fixation on RNA and miRNA-Seq profiles","volume":"9","author":"Jones","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0365","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13059-015-0734-x","article-title":"Errors in RNA-Seq quantification affect genes of relevance to human disease","volume":"16","author":"Robert","year":"2015","journal-title":"Genome Biol"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0370","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J Mol Diagn"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0375","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2022.100969_bb0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17095-7","article-title":"IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms","volume":"11","author":"Nadeu","year":"2020","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.blre.2022.100969_bb0385","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.2020008311","article-title":"IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics","volume":"137","author":"Nadeu","year":"2021","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0390","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.blre.2022.100969_bb0395","article-title":"Profiling immunoglobulin repertoires across multiple human tissues using RNA sequencing","volume":"11","author":"Mandric","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0400","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nbt.3979","article-title":"Antigen receptor repertoire profiling from RNA-seq data","volume":"35","author":"Bolotin","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"23","key":"10.1016\/j.blre.2022.100969_bb0405","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics."},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/gm403","article-title":"HLA typing from RNA-Seq sequence reads","volume":"4","author":"Boegel","year":"2012","journal-title":"Genome Med"},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0415","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/gm396","article-title":"Derivation of HLA types from shotgun sequence datasets","volume":"4","author":"Warren","year":"2012","journal-title":"Genome Med"},{"issue":"21","key":"10.1016\/j.blre.2022.100969_bb0420","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1093\/bioinformatics\/btab628","article-title":"pepsickle rapidly and accurately predicts proteasomal cleavage sites for improved neoantigen identification","volume":"37","author":"Weeder","year":"2021","journal-title":"Bioinformatics."},{"issue":"1\u20132","key":"10.1016\/j.blre.2022.100969_bb0425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00251-005-0781-7","article-title":"The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage","volume":"57","author":"Nielsen","year":"2005","journal-title":"Immunogenetics."},{"issue":"Web server issue","key":"10.1016\/j.blre.2022.100969_bb0430","doi-asserted-by":"crossref","first-page":"W202","DOI":"10.1093\/nar\/gki587","article-title":"Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences","volume":"33","author":"Bhasin","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0435","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0440","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide-MHC Class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2022.100969_bb0445","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/1471-2105-10-296","article-title":"An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction","volume":"10","author":"Nielsen","year":"2009","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0450","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3892\/mmr.2017.6336","article-title":"A three-caller pipeline for variant analysis of cancer whole-exome sequencing data","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0455","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell."},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0460","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41576-021-00367-3","article-title":"Towards population-scale long-read sequencing","volume":"22","author":"De Coster","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0465","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41576-020-0236-x","article-title":"Long-read human genome sequencing and its applications","volume":"21","author":"Logsdon","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0470","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0475","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/1389202918666170329110349","article-title":"Recurrent fusion genes in leukemia: an attractive target for diagnosis and treatment","volume":"18","author":"Wang","year":"2017","journal-title":"Curr Genomics"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0480","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s41467-017-01343-4","article-title":"Mapping and phasing of structural variation in patient genomes using nanopore sequencing","volume":"8","author":"Cretu Stancu","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0485","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1038\/s41596-019-0133-y","article-title":"Mass spectrometry\u2013based identification of MHC-bound peptides for immunopeptidomics","volume":"14","author":"Purcell","year":"2019","journal-title":"Nat Protoc"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0490","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.12936","article-title":"Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry","volume":"154","author":"Freudenmann","year":"2018","journal-title":"Immunology."},{"key":"10.1016\/j.blre.2022.100969_bb0495","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0500","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","article-title":"The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy","volume":"133","author":"Bilich","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100969_bb0505","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jprot.2014.07.009","article-title":"Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes","volume":"109","author":"Hassan","year":"2014","journal-title":"J Proteomics"},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0510","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1074\/mcp.O113.034181","article-title":"Status of large-scale analysis of post-translational modifications by mass spectrometry","volume":"12","author":"Olsen","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.blre.2022.100969_bb0515","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molimm.2020.04.008","article-title":"In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies","volume":"123","author":"Pandey","year":"2020","journal-title":"Mol Immunol"},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0520","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1021\/pr4003245","article-title":"Protein expression profiling of formalin-fixed paraffin-embedded tissue using recombinant antibody microarrays","volume":"12","author":"Pauly","year":"2013","journal-title":"J Proteome Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0525","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nbt.3932","article-title":"Neoantigen prediction and the need for validation","volume":"35","author":"Vitiello","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0530","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/bies.200800234","article-title":"B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin","volume":"31","author":"Cobaleda","year":"2009","journal-title":"BioEssays."},{"issue":"22","key":"10.1016\/j.blre.2022.100969_bb0535","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1182\/blood-2012-05-429811","article-title":"Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia","volume":"120","author":"Gawad","year":"2012","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0540","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2022.100969_bb0545","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.blre.2022.100969_bb0550","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica."},{"issue":"7137","key":"10.1016\/j.blre.2022.100969_bb0555","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature."},{"issue":"7642","key":"10.1016\/j.blre.2022.100969_bb0560","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature21076","article-title":"Metabolic gatekeeper function of B-lymphoid transcription factors","volume":"542","author":"Chan","year":"2017","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.blre.2022.100969_bb0565","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0570","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pbc.22628","article-title":"Frequencies of ETV6\u2013RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west","volume":"55","author":"Liang","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0575","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.4049\/jimmunol.1501291","article-title":"Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells","volume":"195","author":"Manlove","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2022.100969_bb0580","first-page":"125","article-title":"Personalized peptide-vaccination for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants (iVacALL)","volume":"39","author":"Lang","year":"2016","journal-title":"Oncol Res Treat"},{"issue":"S1","key":"10.1016\/j.blre.2022.100969_bb0585","article-title":"IVacALL: A personalized peptidevaccination design platform for pediatric acute lymphoblastic leukemia patients based on patientindividual tumor-specific variants","volume":"4","author":"Rabsteyn","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0590","article-title":"Personalized peptide vaccination based on patientindividual tumor-specific variants induces T-cell responses in pediatric patients","volume":"7","author":"Rabsteyn","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2022.100969_bb0595","first-page":"518","article-title":"IVAC-all-1: Interim analysis of a phase I\/II clinical study on personalized peptide vaccination based on patient-individual tumor-specific variants in relapsed pediatric acute lymphoblastic leukemia","volume":"54","author":"Rabsteyn","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2022.100969_bb0600","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"7574","key":"10.1016\/j.blre.2022.100969_bb0605","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature."},{"issue":"14","key":"10.1016\/j.blre.2022.100969_bb0610","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2022.100969_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1011527","article-title":"Antileukemia T-cell responses in CLL \u2013 We don\u2019t need no aberration","volume":"4","author":"Kowalewski","year":"2015","journal-title":"OncoImmunology."},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0620","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.1073\/pnas.1416389112","article-title":"HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)","volume":"112","author":"Kowalewski","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0625","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3324\/haematol.2016.154039","article-title":"Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14","volume":"102","author":"Hertzberg","year":"2017","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0630","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/2159-8290.CD-20-0174","article-title":"Toward a new molecular taxonomy of diffuse large B-cell lymphoma","volume":"10","author":"Ennishi","year":"2020","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0635","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2022.100969_bb0640","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2022.100969_bb0645","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104504118","article-title":"Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma","volume":"118","author":"Fangazio","year":"2021","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0650","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, Phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0655","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100969_bb0660","series-title":"Enhanced detection of the t (14; 18) translocation in malignant lymphoma using pulsed-field gel electrophoresis","first-page":"1552","author":"Zelenetz","year":"1991"},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0665","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.13239","article-title":"Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression","volume":"93","author":"\u00c9va","year":"2008","journal-title":"Haematologica."},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0670","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2012.074252","article-title":"Somatic hypermutation analysis in follicular lymphoma provides evidence suggesting bidirectional cell migration between lymph node and bone marrow during disease progression and relapse","volume":"98","author":"Wartenberg","year":"2013","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0675","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/leu.2014.209","article-title":"Genomic and epigenomic co-evolution in follicular lymphomas","volume":"29","author":"Loeffler","year":"2015","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0680","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0685","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0690","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1016\/j.blre.2022.100969_bb0695","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jha2.116","article-title":"Genetic aberrations of NLRC5 are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma","volume":"1","author":"Gunawardana","year":"2020","journal-title":"eJHaem."},{"issue":"4","key":"10.1016\/j.blre.2022.100969_bb0700","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2022.100969_bb0705","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-134795","article-title":"Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study","volume":"136","author":"Henneges","year":"2020","journal-title":"Blood."},{"issue":"06","key":"10.1016\/j.blre.2022.100969_bb0710","first-page":"22268805","article-title":"Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma","volume":"01","author":"Ramirez","year":"2022","journal-title":"medRxiv"},{"issue":"20","key":"10.1016\/j.blre.2022.100969_bb0715","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.100969_bb0720","series-title":"Swerdlow SH CE","first-page":"285","article-title":"Mantle cell lymphoma","author":"Swerdlow","year":"2017"},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0725","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0730","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ng1177","article-title":"Spatial proximity of translocation-prone gene loci in human lymphomas","volume":"34","author":"Roix","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0735","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0740","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0745","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3324\/haematol.2020.274258","article-title":"Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma","volume":"107","author":"Ma","year":"2022","journal-title":"Haematologica."},{"issue":"10272","key":"10.1016\/j.blre.2022.100969_bb0750","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0755","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0760","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia."},{"issue":"15","key":"10.1016\/j.blre.2022.100969_bb0765","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.blre.2022.100969_bb0770","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.blre.2022.100969_bb0775","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J"},{"issue":"42","key":"10.1016\/j.blre.2022.100969_bb0780","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1038\/s41388-021-02005-y","article-title":"Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma","volume":"40","author":"Dong","year":"2021","journal-title":"Oncogene."},{"issue":"20","key":"10.1016\/j.blre.2022.100969_bb0785","doi-asserted-by":"crossref","first-page":"e129466","DOI":"10.1172\/JCI129466","article-title":"Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma","volume":"131","author":"Peri","year":"2021","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.blre.2022.100969_bb0790","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","article-title":"Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients","volume":"104","author":"John","year":"2019","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.blre.2022.100969_bb0795","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219825","article-title":"HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy","volume":"6","author":"Nelde","year":"2016","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.blre.2022.100969_bb0800","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s00262-018-2242-9","article-title":"Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities","volume":"67","author":"Weber","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.blre.2022.100969_bb0805","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","article-title":"Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance","volume":"115","author":"Henry","year":"2010","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0810","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ijc.29366","article-title":"CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes","volume":"137","author":"Vauchy","year":"2015","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1016\/j.blre.2022.100969_bb0815","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1080\/10428194.2020.1805113","article-title":"Therapeutic vaccines for aggressive B-cell lymphoma","volume":"61","author":"Xu-Monette","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2022.100969_bb0820","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2022.100969_bb0825","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.7150\/thno.38742","article-title":"Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics."},{"issue":"10","key":"10.1016\/j.blre.2022.100969_bb0830","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur J Immunol"},{"issue":"S12","key":"10.1016\/j.blre.2022.100969_bb0835","doi-asserted-by":"crossref","first-page":"xii11","DOI":"10.1093\/annonc\/mdx681","article-title":"Preclinical and clinical development of neoantigen vaccines","volume":"28","author":"Li","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2022.100969_bb0840","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0160-y","article-title":"Adjuvants for peptide-based cancer vaccines","volume":"4","author":"Khong","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0845","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL priming by exact peptide epitopes in incomplete Freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity","volume":"179","author":"Bijker","year":"2007","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0850","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.blre.2022.100969_bb0855","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"issue":"6533","key":"10.1016\/j.blre.2022.100969_bb0860","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0865","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2022.100969_bb0870","article-title":"Adoptive cell therapy targeting neoantigens: a frontier for cancer research","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.blre.2022.100969_bb0875","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2022.100969_bb0880","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","article-title":"Genetically engineered T cells for cancer immunotherapy","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.blre.2022.100969_bb0885","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intimm\/dxw022","article-title":"T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells","volume":"28","author":"Ikeda","year":"2016","journal-title":"Int Immunol"},{"issue":"8","key":"10.1016\/j.blre.2022.100969_bb0890","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013specific TCR\u2013engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100969_bb0895","doi-asserted-by":"crossref","first-page":"e1929726","DOI":"10.1080\/2162402X.2021.1929726","article-title":"Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma","volume":"10","author":"Wei","year":"2021","journal-title":"OncoImmunology."},{"issue":"7885","key":"10.1016\/j.blre.2022.100969_bb0900","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-021-04061-6","article-title":"Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs","volume":"599","author":"Yarmarkovich","year":"2021","journal-title":"Nature."},{"key":"10.1016\/j.blre.2022.100969_bb0905","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.23","article-title":"An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity","volume":"3","author":"Maus","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.blre.2022.100969_bib906","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-020-01018-6","article-title":"How we treat mature B-cell neoplasms (indolent B-cell lymphomas)","volume":"14","author":"Lumish","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100969_bib907","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ajh.25696","article-title":"Follicular lymphoma: 2020 update on diagnosis and management","volume":"95","author":"Freedman","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:16Z","timestamp":1759436896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":183,"alternative-id":["S0268960X22000431"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100969","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoantigens \u2013 the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100969"}}